HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.

Biomedicines · 2022 · PMC8962361 · PMID 35203582

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Additionally, 0.5 μM vorinostat only showed a trend towards increased NY-ESO-1 expression at the mRNA level (vorinostat/DMSO: 1.37 ± 0.11 fold, p = 0.06, Figure 2 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.